Cytogenetic, interphase fluorescent in situ hybridization (FISH) and RT-PCR methods were
used to study minimal residual disease in peripheral blood stem cells collected for …

In recent years, the prognosis of chronic myeloid leukemia (CML) has been greatly improved
either with interferon-(IFN-) therapy or allogeneic bone marrow transplantation (BMT). In …

To determine the source of residual disease detected in patients with chronic myeloid
leukaemia (CML) in complete cytogenetic remission (n= 8) after treatment with interferon‐α …

Fifteen chronic myelocytic leukemia patients in durable complete cytogenetic conversion
(CCC) under interferon therapy, were monitored every three to six months by bone marrow …

Persistence of BCR-ABL rearrangements was demonstrated by D-FISH technique in chronic
myeloid leukemia (CML) patients in complete cytogenetic response (CCR) after allogeneic …

Interferon (IFN) therapy has become widely used for the treatment of chronic myelogenous
leukemia. Hematologic remissions can be induced in about 60% of patients. Moreover, in a …

Complete hematologic and cytogenetic responses can be obtained with interferon-α (IFN-α)
in 15–25% of the patients with chronic myelogenous leukemia (CML). In these patients …

We measured using a competitive quantitative polymerase chain reaction-capillary
electrophoresis (PCR-CE)-based assay, the levels of bcr-abl transcripts in 44 patients with …

We report minimal residual disease evaluation in 18 chronic myelocytic leukemia patients
who achieved a durable complete cytogenetic conversion (CCC) under interferon alpha …

We analysed 459 samples from 206 chronic myeloid leukaemia (CML) patients at diagnosis
and during or after treatment with interferon‐α (IFN‐α) by quantitative Southern blot analysis …